For the sake of something fun, page-6

the probability of European approval to be 90% according to Wilsons Equity Reseach

‘Overweight’: Upgrade anticipating European approvalOn January 30, in an update on the company, Wilsons Equity Research confirmed that it has an optimistic view of OSL.Wilsons moved further “OVERWEIGHT” on the stock in anticipation of the imminent European approval for OncoSilTM, plus OncoSil’s pursuit of a humanitarian approval in the USA.Wilsons lifted its 12-month target price to $0.30, a 122% premium to the current 13.5 cent share price. Plus, its signalled that catalysts over the next 3-4 years could support valuation gains up to $1.20 per share.

This valuation lift comes after Wilsons determined the probability of European approval to be 90%, up from 60% prior to receipt of the positive CE Mark Status Report. It also recognised that the clinical trial data supporting the OncoSilTM product has continued to improve in terms of patient survival.

DYOR!